Brief: Chinook Therapeutics Receives Orphan Drug Designation From European Commission For BION-1301
05/07/2022 13:14
July 5 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM
EUROPEAN COMMISSION FOR BION-1301 FOR TREATMENT OF PRIMARY IGA
NEPHROPATHY (IGAN)
Source text for Eikon: ID:nGNX9c1ktj
Further company coverage: KDNY.O
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc